Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-10-28

Reporting Person: Madan Ajay (Chief Development Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-28	Common Stock	M	106383	$0.73	Acquired	184671	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-28	Stock Option (right to buy)	$0.73	M	106383	Disposed	2028-03-16	Common Stock (106383)	Direct

Footnotes

F1: Includes 772 shares acquired under the Issuer's Employee Stock Purchase Plan since the last Section 16 filing by the Reporting Person.

F2: 25% of the shares subject to the option vested on July 17, 2017 and 1/48th of the total remaining number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.